Key insights
- Nxera Pharma is suing OMass Therapeutics for patent infringement related to its miniG technology. While the stock has performed well recently, the lawsuit introduces uncertainty. Separately, Eli Lilly's acquisition of Centessa, which includes compounds developed using Nxera's technology, is a positive but indirect development. Overall, a slightly negative signal for US equities due to increased legal risk in the biotech sector.
TOKYO and LONDON - Nxera Pharma Co., Ltd. (TSE:4565) announced today that its subsidiary Nxera Pharma UK Limited has filed patent infringement proceedings against OMass Therapeutics in the Patents Court of the High Court of Justice of England and Wales. The company’s stock has surged 41% over the past six months, trading near its 52-week high of $7.03.
The lawsuit alleges infringement of two patents, EP 3 408 286 B1 and GB 2 558 968 B, which relate to Nxera’s miniG technology, according to a press release statement. The miniG technology is part of the company’s NxWave GPCR-focused structure-based drug discovery platform.
Nxera is seeking compensation and injunctive relief to prevent further infringement. The company stated it does not intend to comment further while the matter is before the court.
Nxera Pharma operates locations in Tokyo, Osaka, London, Cambridge, Basel, and Seoul. The company develops and commercializes medicines in Japan and the Asia-Pacific region while advancing a drug discovery pipeline internally and through partnerships with pharmaceutical and biotechnology companies. For deeper insights into Nxera’s financial health and growth prospects, InvestingPro offers a comprehensive Pro Research Report with expert analysis and actionable intelligence.
In other recent news, Nxera Pharma Co Ltd reported its financial results for the fourth quarter of 2025, showing a slight increase in total revenue to JPY 29.6 billion from JPY 28.8 billion the previous year. Despite this revenue growth, the company experienced a core operating loss and a decrease in milestone revenue. Additionally, Eli Lilly and Company announced a definitive agreement to acquire Centessa Pharmaceuticals Limited. This acquisition focuses on Centessa’s orexin receptor 2 (OX2R) agonist pipeline, which includes compounds like cleminorexton, ORX142, and ORX489. These compounds were developed through a collaboration with Nxera, utilizing the NxStaR technology platform. These developments reflect ongoing strategic moves and financial performance shifts within the pharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.